EA201790296A1 - Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9 - Google Patents

Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9

Info

Publication number
EA201790296A1
EA201790296A1 EA201790296A EA201790296A EA201790296A1 EA 201790296 A1 EA201790296 A1 EA 201790296A1 EA 201790296 A EA201790296 A EA 201790296A EA 201790296 A EA201790296 A EA 201790296A EA 201790296 A1 EA201790296 A1 EA 201790296A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine
disease
vector
interest
nucleotide sequence
Prior art date
Application number
EA201790296A
Other languages
English (en)
Other versions
EA038951B1 (ru
Inventor
Бернардо Лосано-Дубернард
Эрнесто Сото-Прианте
Давид Сарфати-Мизрахи
Original Assignee
Групо Индустриаль Пекуарио, С.А. Де К.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Групо Индустриаль Пекуарио, С.А. Де К.В. filed Critical Групо Индустриаль Пекуарио, С.А. Де К.В.
Publication of EA201790296A1 publication Critical patent/EA201790296A1/ru
Publication of EA038951B1 publication Critical patent/EA038951B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Рекомбинантная вакцина, содержащая вектор на основе птичьего аденовируса серотипа 9 (FAdV-9), имеющий по меньшей мере одну встроенную экзогенную нуклеотидную последовательность, кодирующую по меньшей мере один антиген, связанный с представляющим интерес заболеванием, и заменяющую несущественную область генома аденовируса, и фармацевтически приемлемый носитель, вспомогательное вещество и/или наполнитель, где по меньшей мере одна экзогенная нуклеотидная последовательность, кодирующая по меньшей мере один антиген, связанный с представляющим интерес заболеванием, и заменяющая несущественную область генома аденовируса, расположена между нуклеотидами 491 и 2782. Вектор для этой вакцины является стабильным при производстве в промышленном масштабе. Аналогичным образом, даже если эту вакцину вводят в комбинации с вакциной против болезни Марека, обе вакцины вызывают должный иммунный ответ, на который не оказывает влияния подавление действия друг друга. Таким же образом, эффективность рекомбинантной вакцины не нарушается материнскими антителами и способна индуцировать одновременно ранний и устойчивый защитный ответ в случае всего лишь одного применения.
EA201790296A 2014-08-08 2015-08-06 Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9 EA038951B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2014/063809 WO2016020730A1 (es) 2014-08-08 2014-08-08 Vacuna en vector recombinante de adenovirus aviar serotipo 9
PCT/IB2015/055994 WO2016020885A1 (es) 2014-08-08 2015-08-06 Vacuna en vector recombinante de adenovirus aviar serotipo 9

Publications (2)

Publication Number Publication Date
EA201790296A1 true EA201790296A1 (ru) 2017-06-30
EA038951B1 EA038951B1 (ru) 2021-11-15

Family

ID=55263220

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790296A EA038951B1 (ru) 2014-08-08 2015-08-06 Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9

Country Status (14)

Country Link
US (1) US10758608B2 (ru)
EP (1) EP3178938A4 (ru)
JP (1) JP2017526737A (ru)
KR (1) KR20170063552A (ru)
CN (1) CN106661592A (ru)
AR (1) AR101468A1 (ru)
BR (1) BR112017002577A2 (ru)
CA (1) CA2956997A1 (ru)
CO (1) CO2017001614A2 (ru)
EA (1) EA038951B1 (ru)
MX (3) MX2017001742A (ru)
PE (2) PE20221792A1 (ru)
PH (1) PH12017500216B1 (ru)
WO (2) WO2016020730A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017087A1 (en) 2008-08-08 2010-02-11 3M Innovative Properties Company Lightguide having a viscoelastic layer for managing light
WO2016020730A1 (es) * 2014-08-08 2016-02-11 Laboratorio Avi-Mex, S.A. De C.V. Vacuna en vector recombinante de adenovirus aviar serotipo 9
CN108126191B (zh) * 2016-12-01 2021-04-06 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN108653724B (zh) * 2017-04-01 2020-11-27 普莱柯生物工程股份有限公司 一种用于预防禽减蛋综合征的疫苗组合物、及其制备方法和应用
CN110680914B (zh) * 2019-09-23 2021-11-26 洛阳职业技术学院 一种三联灭活疫苗及其制备方法
CN111494617A (zh) * 2020-04-08 2020-08-07 扬州优邦生物药品有限公司 一种四联灭活疫苗及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103939A (en) * 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
US6296852B1 (en) * 1993-04-14 2001-10-02 Commonwealth Scientific And Industrial Research Organisation Recombinant avian adenovirus vector
NZ263772A (en) 1993-04-14 1996-12-20 Webster Arthur Pty Ltd Recombinant avian adenovirus with heterologous nucleotide sequence; use as vector; vaccine
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
WO2007072916A1 (ja) * 2005-12-22 2007-06-28 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 卵内接種用ワクチン
KR20110081222A (ko) * 2008-09-26 2011-07-13 어번 유니버시티 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화
EP2353610A4 (en) * 2008-11-19 2013-12-11 Avi Mex S A De C V Lab RECOMBINANT INACTIVATED VIRUS VECTOR VACCINE
WO2016020730A1 (es) * 2014-08-08 2016-02-11 Laboratorio Avi-Mex, S.A. De C.V. Vacuna en vector recombinante de adenovirus aviar serotipo 9
MX2018000353A (es) * 2015-07-10 2018-03-14 Univ Guelph Sistema vector de adenovirus aviar 9 (fadv-9) y metodos asociados.

Also Published As

Publication number Publication date
KR20170063552A (ko) 2017-06-08
PE20221792A1 (es) 2022-11-25
CA2956997A1 (en) 2016-02-11
MX2022000718A (es) 2022-02-24
US10758608B2 (en) 2020-09-01
MX2017001742A (es) 2017-05-15
AR101468A1 (es) 2016-12-21
WO2016020730A1 (es) 2016-02-11
PE20170429A1 (es) 2017-05-11
EA038951B1 (ru) 2021-11-15
BR112017002577A2 (pt) 2018-02-27
EP3178938A1 (en) 2017-06-14
PH12017500216A1 (en) 2017-07-03
WO2016020885A1 (es) 2016-02-11
EP3178938A4 (en) 2018-03-21
US20170232096A1 (en) 2017-08-17
JP2017526737A (ja) 2017-09-14
PH12017500216B1 (en) 2017-07-03
CN106661592A (zh) 2017-05-10
CO2017001614A2 (es) 2017-07-28
MX2022003590A (es) 2022-05-26

Similar Documents

Publication Publication Date Title
EA201790296A1 (ru) Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9
Channappanavar et al. T cell-mediated immune response to respiratory coronaviruses
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
CL2018003769A1 (es) Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
EA201892735A1 (ru) Состав вакцины против hiv
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
MX2016002891A (es) Virus recombinantes de la enfermedad de marek y usos de los mismos.
MX2022006602A (es) Vacunas de herpesvirus de pavo recombinante y uso de las mismas.
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
MX366836B (es) Celulas aviares para la produccion mejorada de virus.
ES2721159T3 (es) Antígenos asociados a tumor independientes de MHC novedosos
EA201890274A1 (ru) Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы
WO2014153168A3 (en) Porcine astrovirus sequences and uses thereof
MX2019007924A (es) Vacunas contra la influenza.
ES2689797T3 (es) Vacuna de virus Sendai modificado y vector para la obtención de imágenes
BR112014001287A2 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
GT201400199A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
NZ618125A (en) Genetic vaccines against hendra virus and nipah virus
UA116658U (uk) Атенуйований штам вірусу хвороби марека першого серотипу 4/11 як складовий компонент полівалентної культуральної вакцини проти хвороби марека
MX2014014089A (es) Peptido recombinante de la porina de 42-kda, uso como antigeno vacunal y en la deteccion de anticuerpos contra histophilus somni.
UA119801U (uk) Вірус-вакцина-2 проти інфекційної бурсальної хвороби птиці (хвороби гамборо) зі штаму "ум-93"